"rationale","id","uuid:ID","versionIdentifier","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","753966ea-be58-4bf4-99e5-9303908a1b7a","2","StudyVersion"
